Keros Therapeutics (KROS) Projected to Release Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is anticipated to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.96) per share and revenue of $14.76 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). On average, analysts expect Keros Therapeutics to post ($5.27) EPS for the current fiscal year and ($6.39) EPS for the next fiscal year.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $11.26 on Wednesday. The firm’s fifty day simple moving average is $11.25 and its 200-day simple moving average is $12.26. Keros Therapeutics has a 1-year low of $9.69 and a 1-year high of $22.55.

Keros Therapeutics declared that its Board of Directors has approved a share repurchase plan on Wednesday, September 9th that permits the company to repurchase $5 million in shares. This repurchase authorization permits the company to purchase up to 2.3% of its shares through open market purchases. Stock repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Zacks Research upgraded shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Tuesday, August 4th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Keros Therapeutics in a report on Tuesday, August 4th. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Hold” and an average target price of $20.50.

Insider Activity

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the transaction, the insider directly owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 5,343 shares of company stock valued at $54,985. 12.60% of the stock is currently owned by corporate insiders.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.